Navigation Links
Micromet, Inc. To Regain Rights to Blinatumomab in North America; Reports Financial Results for the Fourth Quarter and Full Year ended December 31, 2008
Date:3/12/2009

n the Committed Equity Financing Facility with Kingsbridge, and our plans regarding collaborations and other partnering activities. You are urged to consider statements that include the words "ongoing," "may," "will," "believes," "potential," "expects," "plans," "anticipates," "intends," or the negative of those words or other similar words to be uncertain and forward-looking. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include the risk that product candidates that appeared promising in early research, preclinical studies or clinical trials do not demonstrate safety and/or efficacy in subsequent clinical trials, the risk that encouraging results from early research, preclinical studies or clinical trials may not be confirmed upon further analysis of the detailed results of such research, preclinical study or clinical trial, the risk that additional information relating to the safety, efficacy or tolerability of our product candidates may be discovered upon further analysis of preclinical or clinical trial data, the risk that we or our collaborators will not obtain approval to market our product candidates, the risks associated with reliance on outside financing to meet capital requirements, and the risks associated with reliance on collaborators, including MedImmune, Merck Serono, TRACON and Nycomed, for the funding or conduct of further development and commercialization activities relating to our product candidates. These factors and others are more fully discussed in Micromet's Quarterly Report on Form 10-Q for the quarter ended September 30, 2008, filed with the SEC on November 6, 2008, as well as other filings by the company with the SEC.

(Tables Follow)

    Micromet, Inc.
    Condensed Consolidated Balance Sheets
    (In thousands, except par value)

                                               December 31,   December 31,
  
'/>"/>
SOURCE Micromet, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Micromet, Inc. Reports Third Quarter 2008 Financial Results
2. Micromet, Inc. to Host Conference Call and Webcast to Discuss Third Quarter 2008 Financial Results
3. Micromet, Inc. Fills Audit Committee Vacancy and Regains Compliance With NASDAQ Marketplace Rule
4. Micromet, Inc. Appoints Barclay Phillips as Senior Vice President and Chief Financial Officer
5. Micromet, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
6. Micromet, Inc. to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results
7. Micromet, Inc. Elects Joseph P. Slattery to Board of Directors
8. Micromet, Inc. to Present at the Sal. Oppenheim 2nd European Healthcare Conference
9. Verenium Regains Compliance With Nasdaq Continued Listing Requirement
10. Peregrine Pharmaceuticals Receives Additional Time to Regain Compliance With NASDAQs Minimum Bid Price Rule
11. Peregrine Pharmaceuticals Receives Letter from NASDAQ Citing Failure to Regain Compliance with Minimum Bid Price Rule
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... 2014 Why did Stephen Hawking become ... so instantly recognizable? Why have they become icons to ... author Hilton Ratcliffe seeks out the answers to those ... to do with science. In " Stephen Hawking Smoked ... 21, 2014), Ratcliffe puts it plainly: , “It ...
(Date:11/21/2014)... 2014 2014 Deep Research Report ... in-depth research report on the transformer market. The ... application, and industry chain structure as well as ... analysis, including China’s domestic market as well as ... situation analysis. The report also covers information on ...
(Date:11/21/2014)... 20, 2014 /CNW/ - Aequus Pharmaceuticals Inc. (the ... it has closed a brokered private placement offering ... C$3.7 million.  Cormark Securities Inc. and Clarus Securities ... Offering for a syndicate of agents that also ... (collectively the "Agents"). Concurrently with the Brokered Offering, ...
(Date:11/21/2014)... GUELPH, ON , Nov. 20, 2014 /PRNewswire/ - BIOREM Inc. (TSXV: ... month and nine month periods ended September 30, 2014.  Biorem,s complete ... SEDAR ( www.sedar.com ). Financial Summary:Three-months ended ... CDN$,000 except per share data) , 2014 , ... , 2,282 , 5,281 , 6,715 ...
Breaking Biology Technology:“Stephen Hawking Smoked My Socks” Sparks Controversy in Science World 2“Stephen Hawking Smoked My Socks” Sparks Controversy in Science World 3“Stephen Hawking Smoked My Socks” Sparks Controversy in Science World 4International Transformer Industry - Analysis on Applications, Development & Forecasts Now Available at ReportsnReports.com 2International Transformer Industry - Analysis on Applications, Development & Forecasts Now Available at ReportsnReports.com 3Aequus Pharmaceuticals closes $4.2 million private placement financing 2Aequus Pharmaceuticals closes $4.2 million private placement financing 3Biorem Reports Third Quarter Results 2Biorem Reports Third Quarter Results 3
... , , TUSTIN, Calif., ... announced that it will release its financial results for the second ... a.m. EST and will host a conference call and webcast to ... , Peregrine,s senior management will discuss financial results for the second ...
... , ... Dr. Susan Jiang, M.D., Ph.D.,Chief Science Officer at Shenzhen Beike Biotechnology ... Diabetic,Foot Care in New Delhi, India, November 22, 2009. Beike is ... The conference, organized by the Indian Podiatry Association (IPA), ...
... , NEW YORK, Dec. 2 Reportlinker.com ... in its catalogue: , Neurostimulation - A Global ... The world neurostimulation market stands enthused by the growing ... age-related diseases such as, Parkinson,s, and Alzheimer,s disease. Widespread ...
Cached Biology Technology:Peregrine Pharmaceuticals to Report Second Quarter FY 2010 Financial Results 2Beike Biotechnology CSO Speaks on Role of Stem Cells in Treating Diabetic Foot Disease at IPA Diabetic Foot Care Conference, India 2Beike Biotechnology CSO Speaks on Role of Stem Cells in Treating Diabetic Foot Disease at IPA Diabetic Foot Care Conference, India 3Reportlinker Adds Neurostimulation - A Global Market Perspective 2Reportlinker Adds Neurostimulation - A Global Market Perspective 3Reportlinker Adds Neurostimulation - A Global Market Perspective 4Reportlinker Adds Neurostimulation - A Global Market Perspective 5Reportlinker Adds Neurostimulation - A Global Market Perspective 6
(Date:11/4/2014)... LAKE CITY, Nov. 5, 2014 – University of Utah ... enzymes to help jet fuel produce electricity without needing ... be used to power portable electronics, off-grid power and ... online today in the American Chemical Society journal ... electricity through a chemical reaction between a fuel and ...
(Date:11/4/2014)... Fla. (November 4, 2014) — Think about the way ... How do neighboring cells know that they are supposed ... how do these tissues find the correct place and ... answering these crucial questions. , In a new study, ... to communicate with their surrounding neighbors, at the head-trunk ...
(Date:11/4/2014)... HOUSTON – (Nov. 4, 2014) – A majority of ... and that could have serious consequences for the rainforests ... researchers shows the positive impacts lemurs can have on ... impact their disappearance could have on the region,s rich ... rainforest have fruits eaten by lemurs. Lemurs in ...
Breaking Biology News(10 mins):Jet-fueled electricity at room temperature 2The inside story: How the brain and skull stay together 2Gardeners of Madagascar rainforest at risk 2Gardeners of Madagascar rainforest at risk 3
... Five scientists, including two from Simon Fraser University, have ... developing Multiple Sclerosis (MS) can be explained by 475,806 ... commonly screen these variants, looking for genetic links to ... in biology, his thesis supervisor SFU biologist Felix Breden ...
... press release is available in German . ... pointed out that the chemical triclosan is one of ... rivers that are still not sufficiently monitored. With extensive ... more comprehensive than standard monitoring procedures, concentrations of the ...
... and developmental Biology professor Fei Wang and colleagues have ... type of blood stem cell, become the white blood ... tissue damage. This approach offers new insights into the ... improve our ability to treat myeloid diseases like leukemia, ...
Cached Biology News:Scientists deepen genetic understanding of MS 2Triclosan needs to be monitored 2A new technique to study how myeloids become white blood cells 2
... to identify over 150 peptide modifications ... isoforms, protein subsets, and suppress false ... associations and relationships easily. The software ... relative protein expression analysis for discovery ...
... all aspects of classical microscopy in a ... Super Contrast (ASC) objectives coupled with a ... combines flexibility and professional microscopy into one ... the DM-B1 steps into the 21st century ...
... Gene expression profiling allows a high-throuput ... that naturally occuring or artifitially induced changes ... in that system can be detected, studied, ... a broad range of genes at a ...
... agitation and temperature control for microbiology and ... independently and is suitable for DASGIP bioreactors ... volume. Its temperature ranges from approximately 10 ... is equipped with an individual electrical heating ...
Biology Products: